Clinical trials: Haemostatic
Acute Myeloid Leukemia, Acute Myeloid Leukemia in Remission
Reduced Intensity Chemotherapy and Radiation Therapy Before Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies
This clinical trial studies the use of reduced intensity chemotherapy and radiation therapy before donor stem cell transplant in treating patients with hematologic malignancies.
- Conditions
- Acute Myeloid Leukemia, Acute Myeloid Leukemia in Remission, Aplastic Anemia, Chronic Myelomonocytic Leukemia
- Trial name
- NCT02566304
- Testing
- Fludarabine, Total-Body Irradiation, T Cell-Depleted Donor Lymphocyte Infusion
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Multiple Myeloma
A Multicentre, Single-arm, Open-label Safety Study of Lenalidomide Plus Dexamethasone in Previously Treated Subjects With Multiple Myeloma
This is a multi-centre, single-arm treatment study combining lenalidomide plus high dose dexamethasone. Subjects who qualify for participation will receive lenalidomide plus high dose dexamethasone in 4 week cycles.
- Trial name
- NCT00420849
- Testing
- Lenalidomide, Dexamethasone
- Where
- 5 sites in Australia, Austria and 3 more
- Volunteers
- 587 people
- Sponsor
- Celgene Corporation
Chronic Myeloproliferative Disorders, Fanconi Anemia
Research Study in Healthy Volunteers of Patients With Fanconi Anemia, Myeloproliferative Disorders, or Myeloma
RATIONALE: Analyzing tissue and blood samples from healthy volunteers or patients with Fanconi anemia, myelodysplasia, myeloproliferative disorders, or myeloma in the laboratory may help doctors learn more about the causes of…
- Conditions
- Chronic Myeloproliferative Disorders, Fanconi Anemia, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic/Myeloproliferative Neoplasms
- Trial name
- NCT00900055
- Testing
- microarray analysis, polyacrylamide gel electrophoresis, polymerase chain reaction
- Where
- United States
- Volunteers
- 213 people, healthy volunteers welcome
- Sponsor
- OHSU Knight Cancer Institute
Ulcer Bleeding
Second-look Endoscopy in High Risk Patients After Endoscopic Hemostasis to Their Bleeding Peptic Ulcers Improves Their Outcomes
Bleeding peptic ulcer is a common medical emergency. Endoscopic treatment stops bleeding in those actively bleeding from their peptic ulcers, reduces further bleeding, transfusion, surgery and deaths.
- Trial name
- NCT02352155
- Testing
- epinephrine injection or heater probe or hemoclips, Observation only
- Where
- 2 sites in China, Thailand
- Volunteers
- 157 people
- Sponsor
- Chinese University of Hong Kong
Multiple Myeloma
Institut Paoli Calmettes Multiple Myeloma Database
Database of Institut Paoli-Calmettes patients diagnosed with multiple myeloma
- Trial name
- NCT02869555
- Testing
- Data collection
- Where
- France
- Volunteers
- 5,000 people
- Sponsor
- Institut Paoli-Calmettes
Multiple Myeloma Refractory
Study of HuL001 in Relapsed/Refractory Multiple Myeloma Patients
The goal of this clinical trial is to learn if the antibody drug HuL001, combined with Lenalidomide/Dexamethasone works to treat Multiple Myeloma patients.
- Trial name
- NCT07210047
- Testing
- HuL001, Lenalidomide/Dexamethasone
- Where
- Taiwan
- Volunteers
- 21 people
- Sponsor
- HuniLife Biotechnology, Inc.
Breast Cancer, Mastectomy
Post-Operative Outcomes of Low Thermal Dissection vs. Traditional Electrosurgery
Low thermal dissection devices have been introduced as a tool to improve surgical outcomes. PlasmaBlade, a low thermal dissection device, has shown to be associated with effective cutting, and significantly lower temperature than…
- Conditions
- Breast Cancer, Mastectomy, Perfusion; Complications, Hemostasis
- Trial name
- NCT03711916
- Testing
- PlasmaBlade 3.0S
- Where
- 2 sites in United States
- Volunteers
- 20 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Multiple Myeloma
Comparison of 25mg Versus 5 mg Lenalidomide as Maintenance Therapy in Patients With Multiple Myeloma
This trial is a randomised, parallel-group, multicenter phase III study for maintenance therapy with lenalidomide in patients with multiple myeloma who were treated with high-dose therapy and autologous stem cell transplantation…
- Trial name
- NCT00891384
- Testing
- Lenalidomide
- Where
- 5 sites in Germany
- Volunteers
- 194 people
- Sponsor
- Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbH
Multiple Myeloma
VMP Regimen - Safety, Efficacy, and Optimal Dose Finding Study for Patients With Multiple Myeloma
The 3-drug therapy of Bortezomib-Melphalan-Prednisolone (VMP) is a standard therapy that is commonly used currently in South Korea as a first-line treatment for treatment-naïve patients with multiple myeloma who are ineligible…
- Trial name
- VISION (NCT04151615)
- Where
- 24 sites in South Korea
- Volunteers
- 203 people
- Sponsor
- Boryung Pharmaceutical Co., Ltd
Chemotherapy-induced Symptomatic Anaemia, Solid Tumours
Biosimilar Retacrit™ (Epoetin Zeta) in the Treatment of Chemotherapy-Induced Symptomatic Anaemia in Haematology and Oncology
The purpose of this study is to observe correction of haemoglobin (Hb) levels in patients receiving chemotherapy as a consequence of a solid tumour, a malignant lymphoma or a multiple myeloma and who are treated with Retacrit™.
- Conditions
- Chemotherapy-induced Symptomatic Anaemia, Solid Tumours, Malignant Lymphomas, Multiple Myeloma
- Trial name
- NCT01626547
- Where
- 39 sites in Germany
- Volunteers
- 291 people
- Sponsor
- Hospira, now a wholly owned subsidiary of Pfizer
Multiple Myeloma
High Dose Sequential Therapy and Autologous Stem Cell Rescue for Multiple Myeloma
To assess the role of autologous hematopoietic cell rescue in the treatment of multiple myeloma.
- Trial name
- NCT00186238
- Testing
- high dose chemotherapy then autologous hematopoietic cell transplant
- Where
- United States
- Volunteers
- 300 people
- Sponsor
- Stanford University
MULTIPLE MYELOMA (MM)
Evaluation of the Safety and the Efficacy of Carfilzomib Combined With Cyclophosphamide and Dexamethasone (CCyd) or Lenalidomide and Dex (CRd) Followed by ASCT or 12 Cycles of Carf Combined With Dex and Len for Patients Eligible for ASCT With Newly Diagnosed Multiple Myeloma.
This study will evaluate the safety and the efficacy of carfilzomib combined with cyclophosphamide and dexamethasone (CCyd) or lenalidomide and dexamethasone (CRd) followed by autologous transplantation ASCT or 12 cycles of…
- Trial name
- FORTE (NCT02203643)
- Testing
- Carfilzomib, Cyclophosphamide, Lenalidomide
- Where
- Italy
- Volunteers
- 477 people
- Sponsor
- Mario Boccadoro
Multiple Myeloma
Clinical Trial to Evaluate Zevor-cel (CT053) in Patients With Relapsed and/or Refractory Multiple Myeloma (LUMMICAR STUDY 2)
A phase 1b/2, open label, multi-center, Clinical Study of Chimeric Antigen Receptor T Cells targeting BCMA in patients with relapsed and or refractory multiple myeloma.
- Trial name
- NCT03915184
- Testing
- zevor-cel
- Where
- 13 sites in United States, Canada
- Volunteers
- 105 people
- Sponsor
- CARsgen Therapeutics Co., Ltd.
Coagulopathy
ROTEM Assessment of Modern Crystalloid, Hydroxyethyl Starch and Gelatin Effect on Coagulation
Modern crystalloid and colloid solutions are balanced solutions which are increasingly used in perioperative period. However, studies investigating their negative effect on whole blood coagulation are missing.
- Trial name
- NCT03674684
- Testing
- hydroxyethyl starch
- Where
- Czechia
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- University Hospital, Motol
Multiple Myeloma
UARK 2005-01 Study of Velcade, Thalidomide, and Dexamethasone (VTD) With or Without Adriamycin® in Relapsed/Refractory Patients
The main goal of this study is to evaluate the effectiveness of the combination of these drugs, and whether they can be given safely together.
- Trial name
- NCT00111748
- Testing
- Velcade, Thalidomide, Dexamethasone
- Where
- United States
- Volunteers
- 180 people
- Sponsor
- University of Arkansas
Leukemia, Lymphoma
Impact of an Early Warning System on the Prognosis of Patients With Hematological Malignancies Receiving Intensive Chemotherapy With or Without Hematopoietic Cell Transplantation.
Patients with hematologic malignancies requiring intensive chemotherapy are at risk for life-threatening complications. Organ failure may appear rapidly and delay in initiating life-sustaining interventions may result in…
- Conditions
- Leukemia, Lymphoma, Multiple Myeloma
- Trial name
- ALHERT (NCT06409767)
- Testing
- Real-time calculation of the NEWS with ICU admission if NEWS ≥ 7.
- Where
- 10 sites in France
- Volunteers
- 2,224 people
- Sponsor
- University Hospital, Angers
Multiple Myeloma
2017-03: A Single-Arm, Open-label Study of Anti-Signaling Lymphocytic Activation Molecule F7 (Anti-SLAMF7) Monoclonal Antibody (mAb) Therapy After Autologous Stem Cell Transplant in Patients With Multiple Myeloma
The Total Therapy treatment regimens developed at the Myeloma Institute have demonstrated great improvement in treatment outcomes for multiple myeloma patients.
- Trial name
- NCT03168100
- Testing
- Elotuzumab, Lenalidomide, Dexamethasone
- Where
- United States
- Sponsor
- University of Arkansas
Breast Cancer, Chronic Myeloproliferative Disorders
Ravuconazole in Preventing Fungal Infections in Patients Undergoing Allogeneic Stem Cell Transplantation
RATIONALE: Antifungals such as ravuconazole may be effective in preventing fungal infections in patients undergoing chemotherapy and stem cell transplantation.
- Conditions
- Breast Cancer, Chronic Myeloproliferative Disorders, Gestational Trophoblastic Tumor, Infection
- Trial name
- NCT00064311
- Testing
- ravuconazole
- Where
- United States
- Sponsor
- National Institutes of Health Clinical Center (CC)
Relapsed Refractory Multiple Myeloma
A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)
This is a randomised, multicentre, controlled, open-label, Phase III global study comparing the efficacy and safety of AZD0120 versus standard regimens (DKd [daratumumab, carfilzomib, and dexamethasone], DPd [daratumumab…
- Trial name
- DURGA-4 (NCT07391657)
- Testing
- AZD0120, Daratumumab, Carfilzomib
- Where
- 143 sites in United States, Australia and 13 more
- Volunteers
- 508 people
- Sponsor
- AstraZeneca
Diffuse Large B-cell Lymphoma, Multiple Myeloma
Preliminary Assessment of [18F]BL40 in PET/CT Scans
CXCR4 is type of receptor that has been detected in more than twenty different subtypes of cancers. Most of these cancers are associated with negative symptoms that worsen over time resulting in great disability and poor…
- Conditions
- Diffuse Large B-cell Lymphoma, Multiple Myeloma, Mantle Cell Lymphoma, Marginal Zone Lymphoma
- Trial name
- NCT06224309
- Testing
- 18F-BL40 PET/CT, 18F-FDG PET/CT, Routine Blood Draw - Phase 1 only
- Where
- Canada
- Volunteers
- 30 people
- Sponsor
- British Columbia Cancer Agency